Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-Current Debt (2020 - 2021)

Insight Molecular Diagnostics' Non-Current Debt history spans 2 years, with the latest figure at $178000.0 for Q3 2021.

  • For Q3 2021, Non-Current Debt fell 91.38% year-over-year to $178000.0; the TTM value through Sep 2021 reached $178000.0, down 91.38%, while the annual FY2020 figure was $1.5 million, N/A changed from the prior year.
  • Non-Current Debt for Q3 2021 was $178000.0 at Insight Molecular Diagnostics, down from $541000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $2.6 million in Q2 2020 and bottomed at $178000.0 in Q3 2021.